Literature DB >> 25150791

IgG accumulates in inhibitory hippocampal neurons of experimental antiphospholipid syndrome.

Aviva Katzav1, Assaf Menachem2, Nicola Maggio3, Lea Pollak4, Chaim G Pick5, Joab Chapman2.   

Abstract

Mice immunized with β2-glycoprotein I (β2GPI) are an experimental model of the antiphospholipid syndrome (eAPS) displaying elevated titers of antiphospholipid antibodies (aPL). We presently studied whether the behavioral hyperactivity in eAPS mice is associated with in vivo binding and accumulation of IgG in the brain. At 6 weeks post immunization eAPS mice had significantly higher levels of aPL (1.32 ± 0.28 and 0.02 ± 0.01 AU, p < 0.001 by t-test) compared to adjuvant immunized controls, as measured by ELISA. Significant hyperactivity in a staircase test in the eAPS mice compared to controls was found in stair-climbing (18.4 ± 0.9 and 12.0 ± 1.7, respectively) and rearing measures (23.5 ± 2.1 and 12.5 ± 1.9, p < 0.01 by t-test). Immunofluorescence staining in eAPS mice revealed significant in vivo accumulation of IgG in cortical and hippocampal neurons which was not seen in controls. Staining for IgG was markedly intense in inhibitory interneurons co-stained for GAD67 in the hippocampus of eAPS mice. The integrity of the blood brain barrier (BBB) evaluated by injection of Evans blue (EB) was impaired in eAPS and adjuvant immunized mice compared to naïve mice. Electrophysiological recordings in hippocampal brain slices showed altered response to paired pulse stimulation as well as dysregulation of carbachol-induced γ- oscillations in eAPS mice compared to control. Penetration into the brain and direct interaction of aPL with inhibitory interneurons in the hippocampus may explain the hyperactive behavior of the eAPS mice. A direct role of aPL in causing CNS dysfunction points to these antibodies as an important therapeutic target in APS.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiphospholipid antibodies; Blood brain barrier; Experimental antiphospholipid syndrome; Hippocampus; Hyperactivity; Inhibitory interneurons

Mesh:

Substances:

Year:  2014        PMID: 25150791     DOI: 10.1016/j.jaut.2014.07.006

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  5 in total

1.  Cross-reactivity between annexin A2 and Beta-2-glycoprotein I in animal models of antiphospholipid syndrome.

Authors:  R Weiss; A Bitton; L Nahary; M T Arango; I Benhar; M Blank; Y Shoenfeld; J Chapman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 2.  Autoimmunity in 2014.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

Review 3.  Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy.

Authors:  Thomas Fleetwood; Roberto Cantello; Cristoforo Comi
Journal:  Front Neurol       Date:  2018-11-26       Impact factor: 4.003

Review 4.  Neurological and Neuropsychiatric Manifestations of Antiphospholipid-Antibody Syndrome (APS).

Authors:  Saba Asif; Anoushka Bali; Ashujot Kaur Dang; Daniel A Gonzalez; Rajeswar Kumar
Journal:  Cureus       Date:  2022-06-16

Review 5.  Neuropsychiatric Manifestations of Antiphospholipid Syndrome-A Narrative Review.

Authors:  Yik Long Man; Giovanni Sanna
Journal:  Brain Sci       Date:  2022-01-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.